(+)‐Cyanidanol‐3 in the Treatment of Acute Viral Hepatitis: A Randomized Controlled Trial
Hans Schomerus, Karl H. Wiedmann, Wolfgang Dölle, Herrmann Peerenboom, Georg Strohmeyer, Klaus Balzer, Harald Goebell, Hans K. Dürr, Christian Bode, André L. Blum, Gert Frösner, Wolfram Gerlich, Peter A. Berg, Klaus Dietz – 1 March 1984 – One‐hundred sixty patients (81 cyanidanol, 79 placebo) were included in a double‐blind placebo‐controlled clinical trial to evaluate the effect of 3 gm (+)‐cyanidanol‐3 per day for 8 weeks on the clinical course of acute viral hepatitis and HBsAg elimination. Quantitative determination of HBsAg was performed at frequent intervals.